Online inquiry

IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11965MR)

This product GTTS-WQ11965MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB3&IGF1R gene. The antibody can be applied in Hepatocellular carcinoma (HCC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001005915.1; NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065; 3480
UniProt ID P21860; P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11965MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7708MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GEXMab73
GTTS-WQ10858MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA M9346A
GTTS-WQ2676MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 785
GTTS-WQ10496MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY-2951742
GTTS-WQ4195MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BIIB019
GTTS-WQ6919MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ENB-0040
GTTS-WQ12008MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MM-121
GTTS-WQ1790MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ADCT-402
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW